<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799914</url>
  </required_header>
  <id_info>
    <org_study_id>VS-01</org_study_id>
    <nct_id>NCT02799914</nct_id>
  </id_info>
  <brief_title>Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease</brief_title>
  <official_title>Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease: A Monocenter Post Market Clinical Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>be Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archer Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>be Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post market clinical follow-up study about the Sinus-venous stent. Patients with venous
      iliofemoral occlusive disease are treated with the Sinus-venous stent. This observational
      study will provide 1 year data about safety and efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stent patency</measure>
    <time_frame>12 months</time_frame>
    <description>Patency broken down in primary patency, assisted primary patency and secondary patency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>Index-procedure (intraoperative)</time_frame>
    <description>The index-procedure is the endovascular procedure in which the patient receives the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised venous clinical severity score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural complications</measure>
    <time_frame>Index-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintervention</measure>
    <time_frame>12 months</time_frame>
    <description>Any peripheral venous intervention after the index-procedure to restore patency in the treated segment or outside the treated segment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Venous Vascular Diseases and Syndromes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinus-Venous stent (Optimed GmbH)</intervention_name>
    <description>Stent implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with venous iliofemoral occlusive disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age at study entry is at least 18 years.

          2. Patient must sign the informed consent form prior to the index-procedure.

          3. Patient suffers from acute or chronic venous occlusive disease indicated to be treated
             with a venous stent.

          4. Target lesion is located in the femoral vein, common femoral vein, external iliac
             vein, or common iliac vein.

        Exclusion Criteria:

          1. Intolerance to anticoagulant medication.

          2. Contra-indication for prolonged anticoagulant treatment.

          3. Life expectancy less than 1 year.

          4. Target vessel has been stented before.

          5. Coagulopathy or known uncorrectable bleeding diathesis.

          6. Recent (&lt;1 year) pulmonary embolism.

          7. Pregnancy.

          8. Known hypersensitivity to nitinol and/or nickel.

          9. Known to be, or suspected of being unable to comply with the study protocol (e.g. no
             permanent address, known to be non-compliant or presenting an unstable psychiatric
             history).

         10. Legal incapacity and/or other circumstances rendering the patient unable to understand
             the nature, scope and possible impact of the study.

         11. Patients in custody by juridical order.

         12. Patients who do not agree to the transmission of their coded data within the liability
             of documentation and notification.

         13. Close affiliation with the investigational site: e.g. a close relative of the
             investigator or a possibly dependent person (e.g. employee or student of the
             investigational site).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Lauwers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

